Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Smith & Nephew PLC Remuneration Information 2024

Mar 11, 2024

4588_def-14a_2024-03-11_f7ec5c40-cd9d-4b5c-95ad-829ba671ff84.html

Remuneration Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 4189G

Smith & Nephew Plc

11 March 2024

SMITH & NEPHEW PLC

11 March 2024

NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.

1.   AWARDS MADE UNDER THE DEFERRED SHARE BONUS PLAN

On 8 March 2024, the following awards of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") were granted under the Company's Deferred Share Bonus Plan. The awards have been made in London and are based on the closing Share price on the London Stock Exchange on 7 March 2024 of £10.875.

A portion (50%) of the annual bonus earned by the following Executive Directors for performance during the year to 31 December 2023 has been deferred into share awards. The awards will normally vest on 8 March 2027 (subject to continued achievement of objectives and employment). The Executive Directors will be required to hold the shares (after tax) for a further period of two years to 8 March 2029. The Executive Directors will receive an additional number of shares equivalent to the amount of dividend payable per vested share during the relevant vesting period.

The following relates to individuals included in the below notification:

Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc Ordinary Shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Awards granted on 8 March 2024 under the Smith & Nephew plc Deferred Share Bonus Plan.
Date of Transaction 2024 - 03 - 08
Place of Transaction Grant took place outside a trading venue
Name

(Position)
Status Price (s) Volume(s) Aggregated information
Deepak Nath

(Chief Executive Officer)
Director £10.875 72,005 N/A Single Transaction
Anne-Fran ç oise Nesmes

(Chief Executive Officer)
Director £10.875 37,368 N/A Single Transaction

2.   AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2020

On 8 March 2024, the following awards of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") were granted under the Smith & Nephew Global Share Plan 2020. The awards have been made in London and are based on the closing Share price on the London Stock Exchange on 7 March 2024 of £10.875.

i.          DEFERRED BONUS PLAN AWARDS GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020:

A portion of the annual bonus earned by the following PDMRs for performance during the year to 31 December 2023 has been deferred into share awards. These awards will normally vest in equal annual tranches over three years following the award date, subject to continued achievement of objectives and employment. In the event that objectives are not met in any of the three years, the portion of shares due to vest on the following anniversary will lapse. PDMRs will receive an additional number of shares equivalent to the amount of dividend payable per vested share during the relevant vesting period. 

The following relates to individuals included in the below notification:

Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc Ordinary Shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Deferred Bonus Plan awards granted on 8 March 2024 under the Smith & Nephew Global Share Plan 2020.
Date of Transaction 2024 - 03 - 08
Place of Transaction Grant took place outside a trading venue
Name

(Position)
Status Price (£) Volume Aggregated information
Helen Barraclough

(Group General Counsel and Company Secretary)
PDMR £10.875 9,366 N/A Single Transaction
Paul Connolly

(President, Global Operations)
PDMR £10.875 9,849 N/A Single Transaction
Phil Cowdy

(Chief Corporate Development and Corporate Affairs Officer)
PDMR £10.875 10,093 N/A Single Transaction
Craig Gaffin

President, Global Orthopaedics
PDMR £10.875 5,572 N/A Single Transaction
Rohit Kashyap

(President AWM and Global Commercial Operations)
PDMR £10.875 11,031 N/A Single Transaction
Mizanu Kebede

(Chief Quality & Regulatory Affairs Officer)
PDMR £10.875 11,327 N/A Single Transaction
Elga Lohler

(Chief HR Officer)
PDMR £10.875 14,129 N/A Single Transaction
Vasant Padmanabhan

(President Research & Development ENT)
PDMR £10.875 14,214 N/A Single Transaction
Alison Parkes

(Chief Compliance Officer)
PDMR £10.875 5,474 N/A Single Transaction
Scott Schaffner

(President Sports Medicine)
PDMR £10.875 17,652 N/A Single Transaction

ii.         PERFORMANCE SHARE PROGRAMME 2024 AWARDS GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020

The Remuneration Committee has approved performance conditions attached to the vesting of these awards, which are detailed below. These awards will vest on 8 March 2027, subject to the achievement of the performance conditions which are measured over the period 1 January 2024 to 31 December 2026 as set out below.

The number of shares subject to the above awards are shown at target vesting. Should maximum vesting be achieved, participants will receive twice the number of shares shown below. Participants will receive an additional number of shares equivalent to the amount of dividend payable per vested share during the relevant performance period.

The following relates to all individuals included in this section:

Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc Ordinary Shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Performance Share Awards granted at target on 8 March 2024 under the Smith & Nephew Global Share Plan 2020.
Date of Transaction 2024 - 03 - 08
Place of Transaction Grant took place outside a trading venue
Name

(Position)
Status Price (£) Volume Aggregated information
Helen Barraclough

(Group General Counsel and Company Secretary)
PDMR £10.875 35,803 N/A Single Transaction
Paul Connolly

(President, Global Operations)
PDMR £10.875 43,926 N/A Single Transaction
Phil Cowdy

(Chief Corporate Development and Corporate Affairs Officer)
PDMR £10.875 38,581 N/A Single Transaction
Craig Gaffin

President, Global Orthopaedics
PDMR £10.875 70,920 N/A Single Transaction
Rohit Kashyap

(President AWM and Global Commercial Operations)
PDMR £10.875 98,357 N/A Single Transaction
Mizanu Kebede

(Chief Quality & Regulatory Affairs Officer)
PDMR £10.875 45,088 N/A Single Transaction
Elga Lohler

(Chief HR Officer)
PDMR £10.875 56,239 N/A Single Transaction
Deepak Nath

(Chief Executive Officer)
PDMR £10.875 151,365 N/A Single Transaction
Vasant Padmanabhan

(President Research & Development ENT)
PDMR £10.875 56,577 N/A Single Transaction
Alison Parkes

(Chief Compliance Officer)
PDMR £10.875 10,429 N/A Single Transaction
Scott Schaffner

(Global President Sports Medicine)
PDMR £10.875 85,666 N/A Single Transaction

The performance conditions applying to these awards have been determined by the Remuneration Committee. 

The awards made to the Executive Directors are subject to four performance measures in the proportions shown:

-     Total Shareholder Return (TSR) - 30%;

-     Return on Invested Capital (ROIC) - 30%;

-     Global Revenue Growth - 30%; and

-     Environmental, Social and Governance (ESG) objectives - 10%.

The awards are subject to TSR as follows:

Award vesting as % of salary at date of grant
Sector based peer group FTSE100 peer group
Below the index Nil Nil
Equaling the index 8.6% 8.6%
8% above the index 34.4% 34.4%

Awards vest on a straight-line basis between these points. The maximum has been set significantly above target reflecting the maximum opportunity for outperformance.

The awards are subject to ROIC as follows:

Return on Invested Capital

Year ended 31 December 2026
Award vesting as a % of salary
Below 8.5% Nil
8.5% 17.2%
9.0% 34.4%
10.5% 68.8%

Awards vest on a straight-line basis between these points.

The awards are subject to Revenue Growth as follows:

Revenue Growth

Three years ended 31 December 2026
Award vesting as a % of salary
Below Threshold Nil
Threshold (-8% of target) 17.2%
Target - set by reference to our expectations 34.4%
Maximum or above (+8% of target) 68.8%

Awards vest on a straight-line basis between these points.

The awards are subject to ESG objectives which relate to the Group's strategic priorities in this area, with primary focus on carbon reductions and diversity measures.

Revenue Growth targets for the three years ending 31 December 2026 for these awards, even though now determined, will not be disclosed until the 2026 Annual Report, when the Remuneration Committee will discuss performance against the targets. It is not possible to disclose precise targets at the time of grant to avoid giving commercially sensitive information to our competitors concerning our growth plans.

Sarah Carne

Deputy Company Secretary

Smith & Nephew plc

Tel:  +44 (0)1923 477100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFLTVTILLIS